Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Talmapimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 14/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 2/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 1/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 1/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 1.00 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 1.00 |
| ▸ | ACTR2 | P61160 | 1/20 | 1.00 |
| ▸ | CCR1 | P32246 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Talmapimod SCHEMBL29437775 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| Talmapimod SCHEMBL29394770 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| Talmapimod SCHEMBL14338006 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| Talmapimod SCHEMBL14185104 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| Talmapimod SCHEMBL4779242 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| Talmapimod SCHEMBL2369829 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| Talmapimod SCHEMBL5649978 | 0.99 | MAPK14 (0.98) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL14587886 | 0.92 | MAPK14 (0.85) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL4512542 | 0.91 | MAPK14 (0.83) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL4503552 | 0.91 | MAPK14 (0.83) | MAPK14MAPK11MAPK13MAPK12NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9517241-B2 | Amelioration of intestinal fibrosis and treatment of Crohn's disease | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-12-13 | — | — | US | claimed |
| US-20160166587-A1 | AMELIORATION OF INTESTINAL FIBROSIS AND TREATMENT OF CROHN'S DISEASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-06-16 | — | — | US | claimed |
| WO-2008013823-A3 | CO-CRYSTALS OF (2R-TRANS)-6-CHLORO-5-[[4-[(4-FLUOROPHENYL)METHYL]-2,5-DIMETHYL-1-PIPERAZINYL]CARBONYL]-N,N,1-TRIMETHYL-ALPHA-OXO-1H-INDOLE-3-ACETAMIDE | SCIOS INC (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008013823-A2 | CO-CRYSTALS OF (2R-TRANS)-6-CHLORO-5-[[4-[(4-FLUOROPHENYL)METHYL]-2,5-DIMETHYL-1-PIPERAZINYL]CARBONYL]-N,N,1-TRIMETHYL-ALPHA-OXO-1H-INDOLE-3-ACETAMIDE | SCIOS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166587-A1 | AMELIORATION OF INTESTINAL FIBROSIS AND TREATMENT OF CROHN'S DISEASE | NOD2, NFKBIA, VIP | MAPK14 2171/4885MAPK11 1660/4885MAPK13 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.